Search Bar & Filters
Found 133 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
Researchers are evaluating the combination of rituximab and golcadomide CC-99282 as a front-line, chemo-free treatment for older frail patients newly diagnosed with Diffuse Large B-Cell Non-Hodgkin Lymphoma DLBCL. This phase II, multicenter study focuses on patients aged 80 years or older who are considered frail based on a simplified geriatric assessment sGA and are not candidates for standard anthracycline-based chemotherapy. The study aims to assess efficacy and safety in this vulnerable population. Participants will receive an induction phase consisting of up to 6 cycles, each lasting 28 days. Cycle 1 includes rituximab intravenously on days 1, 8, and 15, golcadomide orally for days 1 to 14, and dexamethasone orally on days 1, 8, 15, and 22. Cycles 2 through 6 involve rituximab on day 1 and golcadomide orally for days 1 to 14. After induction, patients showing at least a partial response may undergo a consolidation phase starting within 6 to 8 weeks, receiving golcadomide orally for up to 6 more cycles. Involved site radiotherapy is permitted at the end of induction for PET-positive areas and may coincide with consolidation treatment. Throughout the study, patients will undergo response assessments after the 4th and 6th induction cycles and midway through consolidation to evaluate disease progression. Imaging such as PETCT or CT scans will be used for response and sarcopenia assessments. Quality of life will be measured at baseline and at multiple points during and after treatment. Follow-up monitoring will continue for 24 months, with visits every 3 months during the first year and every 6 months during the second year. Patients experiencing disease progression will be followed for survival until study completion. The primary outcome is progression-free survival at 24 months.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
Researchers are conducting an observational study called METAMECH focused on breast cancer patients. This study aims to enhance collaboration between basic and clinical research to support precision oncology by understanding how tumor and host cells evolve together. The goal is to improve patient outcomes, such as reducing the chance of cancer recurrence and improving survival, by collecting clinical data and samples over time. The study will include at least 500 breast cancer patients at various stages, following them through their treatments until death or for a minimum of five years. Patients will be enrolled at two key points before tumor sampling such as surgery or biopsy or before starting any new treatment. METAMECH is organized into tiers to manage data and samples, including retrospective and prospective collection, experimental modeling, and linking data with proof-of-concept trials targeting tumor mechanisms. Participants will be regularly monitored with clinical data collection, imaging, and biological sampling. The study will track the number of patients recruited in different tiers every six months and the number triaged into experimental trials. This long-term observation aims to generate insights into breast cancer progression and support the development of new diagnostic and treatment strategies. The study is designed to be flexible to allow comprehensive data capture throughout the patients treatment journey.
Actively Recruiting
Researchers are evaluating treatments for advanced HRD-positive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, and clear cell carcinoma of the ovary in patients who have no residual tumor after primary tumor debulking. This phase II, multicenter, randomized, open-label study compares the recurrence-free survival of patients receiving either 3 cycles of carboplatin plus paclitaxel followed by maintenance therapy with niraparib or 6 cycles of the same chemotherapy plus niraparib maintenance. The study includes patients with specific disease stages FIGO IIIA to IV and uses genetic testing to stratify patients based on tumor characteristics.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Chronic myeloid leukemia CML is a blood cancer caused by the Philadelphia chromosome, which activates the BCR-ABL1 tyrosine kinase. Treatment with tyrosine kinase inhibitors TKIs has transformed CML from a fatal disease into a manageable chronic condition for most patients, though long-term use raises concerns about side effects, including vascular events and hormonal changes that may affect testosterone levels and lead to erectile dysfunction ED. This study observes male patients with chronic-phase CML who started frontline treatment with TKIs such as imatinib, dasatinib, nilotinib, bosutinib, or ponatinib between 2015 and 2022. It includes both a retrospective review of medical records to collect past data on ED onset, lab tests, ECGs, and BCR-ABL levels, and a prospective follow-up over two years to monitor ED development, cardiovascular events, and possible ED resolution in patients stopping treatment. Participants will be monitored through their medical records and regular clinical evaluations during the two-year follow-up. Researchers will track the cumulative incidence of ED, associations between different TKI treatments and ED, ED reversibility, and cardiovascular toxicity. The study involves no extra procedures beyond standard care and aims to better understand the relationship between TKI therapy and ED in men with CML.
Actively Recruiting
Researchers are conducting a prospective observational study to better understand early-onset gastrointestinal EoGI cancer by examining clinical and demographic data, tumor characteristics, and patient lifestyle habits. The study aims to capture a comprehensive picture of this type of cancer in newly diagnosed patients aged 18 to 49 years. This research is carried out across multiple centers in northern Italy, involving diverse hospital settings. Participants include newly diagnosed EoGI cancer patients confirmed by histology, covering colorectal, gastroesophageal, and pancreatic tumors at any disease stage. The study does not alter any cancer treatments patients receive, which continue as per best clinical practice. Researchers focus on collecting detailed patient data without influencing treatment decisions. During the study, participants provide information on their medical history and lifestyle, which researchers use to characterize the cancer features and patient habits. Follow-up assessments occur at six months, one year, and two years to monitor outcomes. The primary outcome is measured one year from enrollment. The total participation duration extends up to two years, with no additional treatment provided by the study.
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
1-10 of 133
1